| Similar Articles |
|---|
 |
The Motley Fool
February 13, 2007
Brian Lawler |
CVT, We Wait for Thee CV Therapeutics' angina treatment could be set for a big boost. But what investors are getting with CVT today is a specialty pharma that is rapidly burning the cash on its balance sheet.   |
The Motley Fool
March 7, 2007
Brian Lawler |
A CV Therapeutics Buying Opportunity? Shares of CV Therapeutics tank after reporting mixed results from a pivotal clinical trial for its lead drug. |
The Motley Fool
April 17, 2008
Brian Lawler |
CVT's Copacetic Cash Management Drugmaker CV Therapeutics signs away a little portion of its royalty stream from a recently approved drug, in order to get a lot back. |
The Motley Fool
August 1, 2008
Brian Lawler |
Holy Moley, CV Therapeutics! With big successes on the regulatory and financial fronts, CV Therapeutics has had a quarter where everything went right. |
The Motley Fool
November 7, 2007
Brian Lawler |
Turnaround Time for CVT CV Therapeutics announces in its third-quarter financial results that it plans to have a better 2008; its angina drug shows promise for treating diabetics. Investors, take note. |
The Motley Fool
April 28, 2008
Brian Lawler |
CV Therapeutics Feels the Love CV Therapeutics announces its second regulatory thumbs-up this month, after its lead drug Ranexa was essentially approved in the European Union. |
The Motley Fool
April 14, 2008
Brian Lawler |
A Little Delay Goes Away for CVT CV Therapeutics can move ahead, now that it has won marketing approval for its cardiac stress agent regadenoson. |
The Motley Fool
September 17, 2008
Brian Lawler |
CV Therapeutics Expands Ranexa's Reach CVT announces that it has finally found a European marketing partner for its angina treatment Ranexa. |
The Motley Fool
November 1, 2006
Brian Lawler |
Waiting for CVT's Trial Results The biopharm reported third-quarter 2006 earnings that were mostly as expected. Investors are just awaiting the clinical trial results from the company's large phase 3 Merlin study testing its marketed angina drug, Ranexa. |
The Motley Fool
July 10, 2006
Brian Lawler |
CV Therapeutics Gets Greenlighted A final trial could secure full FDA approval for angina drug Ranexa. Investors, take note. |
The Motley Fool
January 28, 2009
Brian Orelli |
M&A Off the Beaten Path CV Theraputics gets courted. |
The Motley Fool
September 26, 2006
Brian Lawler |
CVT's Looming Date With Destiny A pivotal trial for its lead drug, Ranexa, is nearing completion. Investors, take note. |
BusinessWeek
February 2, 2004
Gene G. Marcial |
CV Investors: Take Heart Lately, CV Therapeutics is bouncing around on rumors of what the Food & Drug Administration might do about Ranexa, CV's angina treatment. One New York fund manager, who asked not to be identified, is buying shares because he expects a takeover bid. |
The Motley Fool
April 4, 2005
Karl Thiel |
CV Therapeutics' Great Resume With biotechs in the doldrums, this investor goes hunting. |
The Motley Fool
August 7, 2008
Brian Orelli |
The Next Pharma Acquisition The rate of mergers and acquisitions among drugmakers has reached a feverish pace lately, and doesn't show any signs of slowing down anytime soon. Take a look at some likely candidates. |
The Motley Fool
March 12, 2009
Brian Orelli |
2 Suitors Are Better Than 1 Recent drug company acquisitions prove that competition benefits shareholders. |
The Motley Fool
December 9, 2008
Brian Orelli |
The FDA Can't See the Forest or the Trees Forest Laboratories and Cypress Bioscience are still waiting for FDA approval, but now they've got more data to prove their point. |
The Motley Fool
May 27, 2011
Brian Orelli |
What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate. |
The Motley Fool
July 29, 2011
Sean Williams |
Another Day, Another Loss For Cell Therapeutics Cell Therapeutics is giving shareholders that sinking feeling. |
The Motley Fool
December 30, 2008
Brian Orelli |
The FDA Needs a Bake Sale Money seems to be at the root of the problem with the FDA right now. It's pretty clear that fees, even though they're up to over $1 million per marketing application, aren't enough to get things done in a timely manner. |
The Motley Fool
April 3, 2009
Brian Orelli |
Gilead: Helping Investors Cope With the Market Diversifying seems to be paying off for the drugmaker. |
